Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Codexis, Inc. CDXS
$2.66
+$0.02 (0.57%)
На 18:00, 12 мая 2023
Ранг: 2
Ключевые показатели
-
Marketcap
177396892.00000000
-
week52high
13.03
-
week52low
2.67
-
Revenue
138590000
-
P/E TTM
-7
-
Beta
1.64671200
-
EPS
-0.51000000
-
Last Dividend
0.00000000
-
Next Earnings Date
04 мая 2023 г. в 20:00
Описание компании
Codexis, Inc. discovers, develops, and sells enzymes and other proteins. It offers biocatalyst products and services; intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver protein engineering technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used to discover novel biotherapeutic drug candidates for targeted human diseases, as well as for molecular biology and in vitro diagnostic enzymes. It sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| HC Wainwright & Co. | Buy | Buy | 08 авг 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 18 июл 2022 г. |
| Piper Sandler | Overweight | Overweight | 15 июл 2022 г. |
| Cowen & Co. | Outperform | Outperform | 15 июл 2022 г. |
| Stephens & Co. | Overweight | Overweight | 11 мая 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 07 ноя 2022 г. |
| Piper Sandler | Overweight | Overweight | 19 янв 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| NICOLS JOHN J | D | 321426 | 35714 | 24 янв 2023 г. |
| NICOLS JOHN J | D | 823750 | 35714 | 24 янв 2023 г. |
| NICOLS JOHN J | A | 859464 | 35714 | 24 янв 2023 г. |
| NICOLS JOHN J | D | 823750 | 39785 | 23 янв 2023 г. |
| PARKER H STEWART | A | 37878 | 37878 | 16 дек 2022 г. |
| NICOLS JOHN J | D | 357140 | 35714 | 12 дек 2022 г. |
| NICOLS JOHN J | D | 863535 | 35714 | 12 дек 2022 г. |
| NICOLS JOHN J | A | 899249 | 35714 | 12 дек 2022 г. |
| NICOLS JOHN J | D | 863535 | 39785 | 09 дек 2022 г. |
| NICOLS JOHN J | D | 392854 | 35714 | 16 ноя 2022 г. |
Новостная лента
Codexis to Report First Quarter 2023 Financial Results on May 4
GlobeNewsWire
20 апр 2023 г. в 16:05
REDWOOD CITY, Calif., April 20, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced that it will report its financial results for the first quarter of 2023 on Thursday, May 4, 2023, following the close of market. The Company will not be conducting a conference call in conjunction with this financial results release.
Codexis, Inc. (CDXS) Q4 2022 Earnings Call Transcript
Seeking Alpha
23 февр 2023 г. в 22:23
Codexis, Inc. (NASDAQ:CDXS ) Q4 2022 Earnings Conference Call February 23, 2023 4:30 PM ET Company Participants Stephen Dilly - President, CEO & Director Kevin Norrett - COO Sriram Ryali - CFO Conference Call Participants Steven Mah - Cowen Company Brandon Couillard - Jefferies Matthew Hewitt - Craig-Hallum Operator Welcome to the Codexis Fourth Quarter and Full Year 2022 Earnings Conference Call. A question-and-answer session will follow the formal presentation.
Codexis (CDXS) Reports Q4 Loss, Tops Revenue Estimates
Zacks Investment Research
23 февр 2023 г. в 20:19
Codexis (CDXS) delivered earnings and revenue surprises of 17.39% and 4.30%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Codexis to Report Fourth Quarter and Fiscal Year 2022 Financial Results on February 23
GlobeNewsWire
09 февр 2023 г. в 16:05
REDWOOD CITY, Calif., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced that it will report its financial results for the fourth quarter and fiscal year 2022 on Thursday, February 23, 2023, following the close of market. Codexis management will host a conference call and webcast at 4:30 p.m. Eastern Time to discuss the Company's financial results and provide a business update.
Codexis, Inc. (CDXS) Q3 2022 Earnings Call Transcript
Seeking Alpha
05 ноя 2022 г. в 17:15
Codexis, Inc. (NASDAQ:CDXS ) Q3 2022 Earnings Conference Call November 3, 2022 4:30 PM ET Company Participants Brendan Strong - Argot Partners Dr. Stephen Dilly - President and Chief Executive Officer Kevin Norrett - Chief Operating Officer Ross Taylor - Chief Financial Officer Conference Call Participants Chad Wiatrowski - Cowen and Company Matthew Hewitt - Craig-Hallum Capital Group Operator Welcome to the Codexis Third Quarter 2022 Earnings Conference Call. At this time, all participants are in listen-only mode.